Trxade Group

TRxADE HEALTH, Inc. provides an online platform for pharmaceutical purchasers. It owns and operates a business-to-business web-based marketplace focused on the United States pharmaceutical industry. The firm operates a web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories, and services. It also provides state-licensed pharmacies and buying groups in the United States with pharmaceuticals approved by the United States Food and Drug Administration and acts as a technology consultant provider that supports their programming needs and provides research on pharmaceutical pricing and shortages in acute care and retail settings. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

The Company's new focus allows for the sale of non-core assets to capitalize on Eat Well's recently announced prioritization of its global Ag strategy VANCOUVER, BC , June 23, 2023 /PRNewswire/ - Eat Well Investment Group Inc. (CSE: EWG) (US: EWGFF) (FSE: 6BC0), a leading plant-based food ingredient and CPG company, is pleased to announce it has entered into a definitive membership interest purchase agreement (the "MIPA") for its wholly-owned subsidiary, Sapientia Technology Inc., ("Sapientia") to Superlatus, Inc. ("Superlatus"), as part of a NASDAQ merger (the "Merger") with TRxADE HEALTH, Inc. (NASDAQ: MEDS). This strategic move marks Eat Well Group's commitment to sharpening its focus and leveraging its global agricultural strategy by divesting non-core assets.

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. (“Superlatus”), a U.S.-based holding company of food products and distribution capabilities, has signed a binding letter of intent (the “LOI”) to be acquired by TRxADE HEALTH, Inc. (NASDAQ:MEDS) (“TRxADE”), a pharmaceutical exchange platform provider (the “Merger”).

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

One of the biggest movers in today's market is little-known health tech company TRxADE Health (NASDAQ: MEDS ). Shares of MEDS stock have rocketed more than 60% higher as of this writing on an otherwise uneventful day in the market.

TRxADE Health (MEDS) Stock Soars 60% on Reverse Split

Lutz, Florida, June 21, 2023 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (Nasdaq: MEDS) (the “Company”), today announced that its board of directors has approved a 1-for-15 reverse stock split of its common stock. The reverse stock split will take effect at 11:59 p.m. Eastern Time on June 21, 2023 and will be effective at the open of business on June 22, 2023 (the “Effective Time”). As a result, at the Effective Time the Company's 10,210,878 outstanding shares of common stock will be reduced to 680,726.

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Prashant Patel - Interim Chief Financial Officer Suren Ajjarapu - Founder, Chairman and Chief Executive Officer Conference Call Participants Allen Klee - Maxim Group LLC Howard Halpern - Taglich Brothers, LLC Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

TRxADE (MEDS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.12 per share a year ago.

TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates

Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform TAMPA, FL / ACCESSWIRE / May 15, 2023 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the quarter ended March 31, 2023.

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

TAMPA, FL / ACCESSWIRE / May 5, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023.

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TRxADE (MEDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TAMPA, FL / ACCESSWIRE / April 25, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 8, 2023.

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q4 2022 Earnings Conference Call March 27, 2023 5:30 PM ET Company Participants Prashant Patel - CFO Surendra Ajjarapu - Founder, Chairman and CEO Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates

Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform TAMPA, FL / ACCESSWIRE / March 27, 2023 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the year ended December 31, 2022.

TRxADE HEALTH Reports 16% Revenue Growth and Year End 2022 Financial Results

TAMPA, FL / ACCESSWIRE / March 13, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for fourth quarter and year-end 2022, after market close on March 27, 2023.

TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m.

TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy

TAMPA, FL / ACCESSWIRE / December 6, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company") an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a preferred telemedicine services agreement with an independent group purchasing organization (GPO) which will provide deep discounts to access Bonum Health's service platform for 100+ pharmacies and their patient's in the northeastern part of the United States.

Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model

TRxADE (MEDS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

TRxADE (MEDS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About TRxADE (MEDS) Rating Upgrade to Buy

Bed Bath & Beyond

DraftKings

Peloton

Spirit AeroSystems Hlds

Upstart Holdings

Revlon Inc

Meme stocks represented one of the most remarkable developments in the equities space during much of the new normal. However, by 2022, this sector received a very rude awakening.

7 Meme Stocks Smart Investors Shouldn't Touch With a 10-Foot Pole

TRxADE Health, Inc. (NASDAQ:MEDS ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Janet Huffman - CFO & Principal Accounting Officer Surendra Ajjarapu - Founder, Chairman, CEO, Treasurer & Secretary Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, and welcome to TRxADE Conference Call. [Operator Instructions].

TRxADE Health, Inc. (MEDS) Q3 2022 Earnings Call Transcript

TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates

Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform

TRxADE HEALTH Reports Third Quarter Gross Margin of 58% and Q3 2022 Financial Results

TAMPA, FL / ACCESSWIRE / October 24, 2022 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for third quarter 2022, after market close on November 7, 2022.

TRxADE HEALTH, INC. to Report Third Quarter 2022 Financial Results on Monday, November 7th at 5:00 p.m.

LUTZ, FL / ACCESSWIRE / October 4, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.8 million of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering and warrants to purchase common stock in a concurrent private placement.

TRxADE Health Announces Pricing of $1.8 Million Registered Direct Offering

TAMPA, FL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced today the appointment of Mr. Jeff Newell to the Company's Board of Directors. Prior to his appointment to the Board of Directors, Mr. Newell served on the Company's Advisory Board. Mr. Newell will serve as a strategic resource to TRxADE as it continues to develop its trade relationships in the industry.

News for Trxade Group Stock (MEDS)